Resistant hypertension workup and approach to treatment

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Makris, Anastasios ^a   Seferou, Maria ^a   Papadopoulos, Dimitris P ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATRASENTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; LOSARTAN; METHYLDOPA; MINOXIDIL; OMAPATRILAT; RENIN INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; CARDIOVASCULAR RISK; CAROTID BARORECEPTOR STIMULATION; CAROTID SINUS PRESSORECEPTOR; CATHETER ABLATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMORBIDITY; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EXCITATION AND STIMULATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEDICAL DEVICE; PATIENT COMPLIANCE; PATIENT EDUCATION; PERIPHERAL EDEMA; PHEOCHROMOCYTOMA; POSITIVE END EXPIRATORY PRESSURE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PULSE GENERATOR; RESISTANT HYPERTENSION; REVIEW; SLEEP DISORDERED BREATHING; UNSPECIFIED SIDE EFFECT;

EID: 84868280716     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/598694     Document Type: Review

References (109)

1. Wolf-Maier K., Cooper R. S., Banegas J. R., Giampaoli S., Hense H. W., Joffres M., Kastarinen M., Poulter N., Primatesta P., Rodríguez-Artalejo F., Stegmayr B., Thamm M., Tuomilehto J., Vanuzzo D., Vescio F., Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. Journal of the American Medical Association 2003 289 18 2363 2369 2-s2.0-0038047699 10.1001/jama.289.18.2363 (Pubitemid 37430168)
2. World Health Organization, Reducing risks, promoting healthy life. World Health Report 2002 Geneva, Switzerland World Health Organization
3. Calhoun D. A., Jones D., Textor S., Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008 117 25 e510 e526
4. Epstein M., Resistant hypertension: prevalence and evolving concepts. Journal of Clinical Hypertension 2007 9 1 2 6 2-s2.0-34047267839
5. Kaplan N. M., Resistant hypertension. Journal of Hypertension 2005 23 8 1441 1444 2-s2.0-23344447834 (Pubitemid 41104810)
6. Lloyd-Jones D. M., Evans J. C., Larson M. G., O'Donnell C. J., Roccella E. J., Levy D., Differential control of systolic and diastolic blood pressure factors associated with lack of blood pressure control in the community. Hypertension 2000 36 4 594 599 2-s2.0-0033779238
7. Lloyd-Jones D. M., Evans J. C., Larson M. G., Levy D., Treatment and control of hypertension in the community: a prospective analysis. Hypertension 2002 40 5 640 646 2-s2.0-0036840899 10.1161/01.HYP.0000035855.44620.DA (Pubitemid 35278599)
8. Cushman W. C., William.Cushman@med.va.gov Ford C. E., Cutler J. A., Margolis K. L., Davis B. R., Grimm R. H., Black H. R., Hamilton B. P., Holland J., Nwachuku C., Papademetriou V., Probstfield J., Wright Jr. J. T., Alderman M. H., Weiss R. J., Piller L., Bettencourt J., Walsh S. M., Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attact trial (ALLHAT). Journal of Clinical Hypertension 2002 4 6 393 404 (Pubitemid 35469393)
9. Hannila-Handelberg T., tuula.hannila-handelberg@hus.fi Kontula K., kimmo.kontula@hus.fi Tikkanen I., ilkka.tikkanen@helsinki.fi Tikkanen T., tuula.tikkanen@hus.fi Fyhrquist F., frej.fyhrquist@helsinki.fi Helin K., karri.helin@hus.fi Fodstad H., heidi.fodstad@hus.fi Piippo K., kirsi.piippo@hus.fi Meittinen H. E., helena.miettinen@hus.fi Virtamo J., jarmo.virtamo@ktl.fi Krusius T., tom.krusius@veripalvelu.fi Sarna S., seppo.sarna@helsinki.fi Gautschi I., ivn.gautschi@ipharm.unil.ch Schild L., laurent.schild@ipharm.unil.ch Hiltunen T. P., timo.hiltunen@hus.fi Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertension. BMC Medical Genetics 2005 6, article 4 10.1186/1471-2350-6-4 (Pubitemid 41418165)
10. Givens R. C., Lin Y. S., Dowling A. L. S., Thummel K. E., Lamba J. K., Schuetz E. G., Stewart P. W., Watkins P. B., pbwatkins@med.unc.edu CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. Journal of Applied Physiology 2003 95 3 1297 1300 (Pubitemid 37034028)
11. Ho H., Pinto A., Hall S. D., Flockhart D. A., Li L., Skaar T. C., Cadman P., O'Connor D. T., Wagner U., Fineberg N. S., Weinberger M. H., Association between the CYP3A5 genotype and blood pressure. Hypertension 2005 45 2 294 298 2-s2.0-19944431766 10.1161/01.HYP.0000151361.31736.96 (Pubitemid 40179975)
12. Pickering T. G., Hall J. E., Appel L. J., Falkner B. E., Graves J., Hill M. N., Jones D. W., Kurtz T., Sheps S. G., Roccella E. J., Recommendations for blood pressure measurement in humans and experimental animalspart 1: blood pressure measurement in humansa statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on high blood pressure research. Circulation 2005 111 5 697 716 2-s2.0-13444255966 10.1161/01.CIR.0000154900.76284.F6 (Pubitemid 40216499)
13. Caro J. J., Speckman J. L., Salas M., Raggio G., Jackson J. D., Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Canadian Medical Association Journal 1999 160 1 41 46 2-s2.0-0033547741 (Pubitemid 29054225)
14. Mazzaglia G., Mantovani L. G., Sturkenboom M. C. J. M., Filippi A., Trifirò G., Cricelli C., Brignoli O., Caputi A. P., Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. Journal of Hypertension 2005 23 11 2093 2100 2-s2.0-29244462820 (Pubitemid 41830406)
15. van Wijk B. L. G., Klungel O. H., Heerdink E. R., de Boer A., Rate and determinants of 10-year persistence with antihypertensive drugs. Journal of Hypertension 2005 23 11 2101 2107 2-s2.0-28844436931 (Pubitemid 41830407)
16. Wildman R. P., Gu D., Muntner P., Huang G., Chen J., Duan X., He J., Alcohol intake and hypertension subtypes in Chinese men. Journal of Hypertension 2005 23 4 737 743 2-s2.0-17144396306 (Pubitemid 40523271)
17. Henningsen N. C., Ohlsson O., Mattiasson I., Trell E., Kristensson H., Hood B., Hypertension, levels of serum gamma glutamyl transpeptidase and degree of blood pressure control in middle-aged males. Acta Medica Scandinavica 1980 207 4 245 251 2-s2.0-0018831053 (Pubitemid 10148997)
18. Garg J. P., Elliott W. J., Folker A., Izhar M., Black H. R., Resistant hypertension revisited: a comparison of two university-based cohorts. American Journal of Hypertension 2005 18 5 619 626 2-s2.0-18844389740 10.1016/j.amjhyper.2004.11.021 (Pubitemid 40692429)
19. Forman J. P., Stampfer M. J., Curhan G. C., Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005 46 3 500 507 2-s2.0-25444455368 10.1161/01.HYP.0000177437.07240.70 (Pubitemid 41376829)
20. Trewet C. L., Ernst M. E., Resistant hypertension: identifying causes and optimizing treatment regimens. Southern Medical Journal 2008 101 2 166 173 2-s2.0-41249103273
21. Vidt D. G., Pathogenesis and treatment of resistant hypertension. Minerva Medica 2003 94 4 201 214 2-s2.0-0242695644 (Pubitemid 37413349)
22. Brown M. A., Buddle M. L., Martin A., Is resistant hypertension really resistant? American Journal of Hypertension 2001 14 12 1263 1269 2-s2.0-0035216183 10.1016/S0895-7061(01)02193-8 (Pubitemid 33151484)
23. Pickering T. G., Arterial stiffness as a cause of resistant hypertension? Journal of Clinical Hypertension 2007 9 5 390 395 2-s2.0-34948900451 10.1111/j.1524-6175.2007.06300.x
24. Hall J. E., The kidney, hypertension, and obesity. Hypertension 2003 41 3 625 633 2-s2.0-0037340168 10.1161/01.HYP.0000052314.95497.78 (Pubitemid 36314565)
25. Kroon B., European Society of Hypertension 20th Meeting. Abstract 01, Oral Session 9D
26. Calhoun D. A., Resistant or difficult-to-treat hypertension. Journal of Clinical Hypertension 2006 8 3 181 186 2-s2.0-33646880274
27. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jones D. W., Materson B. J., Oparil S., Wright J. T., Roccella E. J., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 42 6 1206 1252 2-s2.0-0347423198 10.1161/01.HYP.0000107251.49515.c2 (Pubitemid 37553153)
28. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S., The occurrence of sleep-disordered breathing among middle-aged adults. New England Journal of Medicine 1993 328 17 1230 1235 2-s2.0-0027462562 10.1056/ NEJM199304293281704 (Pubitemid 23115702)
29. Olivieri O., Ciacciarelli A., Signorelli D., Pizzolo F., Guarini P., Pavan C., Corgnati A., Falcone S., Corrocher R., Micchi A., Cressoni C., Blengio G., Aldosterone to renin ratio in a primary care setting: the Bussolengo study. Journal of Clinical Endocrinology and Metabolism 2004 89 9 4221 4226 2-s2.0-4544267585 10.1210/jc.2003-032179 (Pubitemid 39244414)
30. Logan A. G., Perlikowski S. M., Mente A., Tisler A., Tkacova R., Niroumand M., Leung R. S. T., Bradley T. D., High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. Journal of Hypertension 2001 19 12 2271 2277 2-s2.0-0035215206 10.1097/00004872-200112000-00022 (Pubitemid 33135251)
31. Grote L., Hedner J., Peter J. H., Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. Journal of Hypertension 2000 18 6 679 685 2-s2.0-0034124835 (Pubitemid 30406738)
32. Lavie P., Hoffstein V., Sleep apnea syndrome: a possible contributing factor to resistant. Sleep 2001 24 6 721 725 2-s2.0-0035885140 (Pubitemid 32823738)
33. Somers V. K., Dyken M. E., Clary M. P., Abboud F. M., Sympathetic neural mechanisms in obstructive sleep apnea. Journal of Clinical Investigation 1995 96 4 1897 1904 2-s2.0-0028841211
34. Grassi G., Facchini A., Trevano F. Q., Dell'Oro R., Arenare F., Tana F., Bolla G., Monzani A., Robuschi M., Mancia G., Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005 46 2 321 325 2-s2.0-23244437764 10.1161/01.HYP.0000174243.39897.6c (Pubitemid 41099164)
35. Calhoun D. A., Nishizaka M. K., Zaman M. A., Harding S. M., Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004 125 1 112 117 2-s2.0-1442307014 10.1378/chest.125.1.112 (Pubitemid 38114572)
36. Pratt-Ubunama M. N., Nishizaka M. K., Boedefeld R. L., Cofield S. S., Harding S. M., Calhoun D. A., Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007 131 2 453 459 2-s2.0-33847193562 10.1378/chest.06-1442
37. Setaro J. F., Black H. R., Current concepts: refractory hypertension. New England Journal of Medicine 1992 327 8 543 547 2-s2.0-0027124231
38. Strollo P. J. Jr., Rogers R. M., Obstructive sleep apnea. New England Journal of Medicine 1996 334 2 99 104 2-s2.0-0030579588 (Pubitemid 126532784)
39. Douma S., Petidis K., Doumas M., Papaefthimiou P., Triantafyllou A., Kartali N., Papadopoulos N., Vogiatzis K., Zamboulis C., Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. The Lancet 2008 371 9628 1921 1926 2-s2.0-44649150565 10.1016/S0140-6736(08)60834-X (Pubitemid 351778191)
40. Eide I. K., Torjesen P. A., Drolsum A., Babovic A., Lilledahl N. P., Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. Journal of Hypertension 2004 22 11 2217 2226 2-s2.0-7744227337 10.1097/00004872-200411000-00026 (Pubitemid 39463817)
41. Epstein M., Resistant hypertension: prevalence and evolving concepts. Journal of Clinical Hypertension 2007 9 1, supplement 1 2 6 2-s2.0-34047267839
42. Epstein M., Calhoun D. A., The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy. Current Hypertension Reports 2007 9 2 98 105 2-s2.0-34249113478 10.1007/s11906-007-0018-2 (Pubitemid 46779373)
43. Duprez D. A., Aldosterone and the vasculature: mechanisms mediating resistant hypertension. Journal of Clinical Hypertension 2007 9 1, supplement 1 13 18 2-s2.0-34047260573
44. Engeli S., Böhnke J., Gorzelniak K., Janke J., Schling P., Bader M., Luft F. C., Sharma A. M., Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005 45 3 356 362 2-s2.0-14644395574 10.1161/01.HYP. 0000154361.47683.d3 (Pubitemid 40315803)
45. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., Langenbach J., Willenberg H. S., Barthel A., Hauner H., McCann S. M., Scherbaum W. A., Bornstein S. R., Human adipocytes secrete mineralocorticoid-releasing factors. Proceedings of the National Academy of Sciences of the United States of America 2003 100 2 14211 14216 2-s2.0-10744220710 10.1073/pnas.2336140100 (Pubitemid 37499216)
46. Mosso L., Carvajal C., González A., Barraza A., Avila F., Montero J., Huete A., Gederlini A., Fardella C. E., Primary aldosteronism and hypertensive disease. Hypertension 2003 42 2 161 165 2-s2.0-0042266234 10.1161/01.HYP.0000079505.25750.11 (Pubitemid 36944590)
47. Fardella C. E., Mosso L., Gómez-Sánchez C., Cortés P., Soto J., Gómez L., Pinto M., Huete A., Oestreicher E., Foradori A., Montero J., Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. Journal of Clinical Endocrinology and Metabolism 2000 85 5 1863 1867 2-s2.0-17744390208 10.1210/jc.85.5.1863 (Pubitemid 32269290)
48. Gordon R. D., Stowasser M., Tunny T. J., Klemm S. A., Rutherford J. C., High incidence of primary aldosteronism in 199 patients referred with hypertension. Clinical and Experimental Pharmacology and Physiology 1994 21 4 315 318 2-s2.0-0028216558 (Pubitemid 24201225)
49. Park J., Campese V., Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. Journal of Clinical Hypertension 2007 9 1, supplement 1 7 12 2-s2.0-34047248060
50. Buckalew V. M. Jr., Berg R. L., Wang S. R., Porush J. G., Rauch S., Schulman G., Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. American Journal of Kidney Diseases 1996 28 6 811 821 2-s2.0-16144363769 (Pubitemid 26412076)
51. Klahr S., Levey A. S., Beck G. J., Caggiula A. W., Hunsicker L., Kusek J. W., Striker G., The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. New England Journal of Medicine 1994 330 13 877 884 10.1056/NEJM199403313301301 (Pubitemid 24094966)
52. Campese V. M., Mitra N., Sandee D., Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney International 2006 69 6 967 973 2-s2.0-33644856338 10.1038/sj.ki.5000177 (Pubitemid 43372170)
53. Aqel R. A., Zoghbi G. J., Baldwin S. A., Abo Auda W. S., Calhoun D. A., Coffey C. S., Perry G. J., Iskandrian A. E., Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. Journal of Hypertension 2003 21 6 1157 1162 2-s2.0-0037865202 10.1097/00004872-200306000- 00016 (Pubitemid 36667870)
54. Crowley J. J., Santos R. M., Peter R. H., Puma J. A., Schwab S. J., Phillips H. R., Stack R. S., Conlon P. J., Progression of renal artery stenosis in patients undergoing cardiac catheterization. American Heart Journal 1998 136 5 913 918 2-s2.0-0031790901 10.1016/S0002-8703(98)70138-3 (Pubitemid 28506893)
55. Ives N. J., Wheatley K., Stowe R. L., Krijnen P., Plouin P. F., van Jaarsveld B. C., Gray R., Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. Nephrology Dialysis Transplantation 2003 18 2 298 304 2-s2.0-0037314935 10.1093/ndt/18.2.298 (Pubitemid 36181680)
56. Safian R. D., Textor S. C., Renal-artery stenosis. New England Journal of Medicine 2001 344 6 431 442 2-s2.0-0035825718 10.1056/NEJM200102083440607 (Pubitemid 32128677)
57. Kawashima A., Francis I. R., Baumgarten D. A., Renovascular Hypertension 2007 Reston, Va, USA American College of Radiology
58. Omura M., Saito J., Yamaguchi K., Kakuta Y., Nishikawa T., Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertension Research 2004 27 3 193 202 2-s2.0-1842867029 10.1291/hypres.27.193 (Pubitemid 38489081)
59. Sinclair A. M., Isles C. G., Brown I., Cameron H., Murray G. D., Robertson J. W., Secondary hypertension in a blood pressure clinic. Archives of Internal Medicine 1987 147 1289 1293
60. Sutton J. M., Sheps S. G., Lie J. T., Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clinic Proceedings 1981 56 6 354 360 2-s2.0-0019832081 (Pubitemid 11093806)
61. Lenders J. W. M., Eisenhofer G., Mannelli M., Pacak K., Phaeochromocytoma. Lancet 2005 366 9486 665 675 2-s2.0-23844520735 10.1016/S0140-6736(05)67139-5 (Pubitemid 41176020)
62. Moneva M. H., Gomez-Sanchez C. E., Pathophysiology of adrenal hypertension. Seminars in Nephrology 2002 22 1 44 53 2-s2.0-0036144631 (Pubitemid 34076054)
63. Arnaldi G., Mancini T., Polenta B., Boscaro M., Cardiovascular risk in Cushing's syndrome. Pituitary 2004 7 4 253 256 2-s2.0-30944438752 10.1007/s11102-005-1172-7 (Pubitemid 43115861)
64. Ferrari P., Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease. Best Practice and Research: Clinical Endocrinology and Metabolism 2003 17 4 575 589 2-s2.0-0344740887 10.1016/S1521-690X(03)00053-8
65. McFarlane S. I., Banerji M., Sowers J. R., Insulin resistance and cardiovascular disease. Journal of Clinical Endocrinology and Metabolism 2001 86 2 713 718 2-s2.0-0035093256 10.1210/jc.86.2.713 (Pubitemid 32207485)
66. Sacerdote A., Weiss K., Tran T., Noor B. R., McFarlane S. I., Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management. Current Hypertension Reports 2005 7 3 212 218 2-s2.0-21244489666 (Pubitemid 40894927)
67. Muiesan M. L., Lupia M., Salvetti M., Grigoletto C., Sonino N., Boscaro M., Agabiti Rosei E., Mantero F., Fallo F., Left ventricular structural andnfunctional characteristics in Cushing's syndrome. Journal of the American College of Cardiology 2003 41 12 2275 2279 2-s2.0-0037971530 10.1016/S0735-1097(03)00493-5 (Pubitemid 36724279)
68. Faggiano A., Pivonello R., Spiezia S., De Martino M. C., Filippella M., Di Somma C., Lombardi G., Colao A., Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. Journal of Clinical Endocrinology and Metabolism 2003 88 6 2527 2533 2-s2.0-0038305844 (Pubitemid 36724418)
69. Papadopoulos D. P., Papademetriou V., Resistant hypertension: diagnosis and management. Journal of Cardiovascular Pharmacology and Therapeutics 2006 11 2 113 118 2-s2.0-33749033117 10.1177/1074248406289735 (Pubitemid 44449100)
70. Yakovlevitch M., Black H. R., Resistant hypertension in a tertiary care clinic. Archives of Internal Medicine 1991 151 9 1786 1792 2-s2.0-0026001631 10.1001/archinte.151.9.1786
71. Hermida R. C., Ayala D. E., Calvo C., López J. E., Mojón A., Fontao M. J., Soler R., Fernández J. R., Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension. 2005 46 4 1053 1059 2-s2.0-33644651744
72. Hermida R. C., Ayala D. E., Fernández J. R., Calvo C., Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 2008 51 1 69 76 2-s2.0-37349007842 10.1161/HYPERTENSIONAHA.107.096933 (Pubitemid 350307106)
73. Moser M., Setaro J. F., Clinical practice. Resistant or difficult-to-control hypertension. New England Journal of Medicine 2006 355 4 385 392 10.1056/NEJMcp041698 (Pubitemid 44127541)
74. Graves J. W., Bloomfield R. L., Buckalew V. M. Jr., Plasma volume in resistant hypertension: guide to pathophysiology and therapy. American Journal of the Medical Sciences 1989 298 6 361 365 2-s2.0-0024814746 (Pubitemid 20026468)
75. Taler S. J., Textor S. C., Augustine J. E., Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002 39 5 982 988 2-s2.0-0036107152 10.1161/01.HYP.0000016176.16042.2F (Pubitemid 34547797)
76. Jamerson K. A., Bakris G. L., Dahlö B., Pitt B., Velazquez E., Gupte J., Lefkowitz M., Hester A., Shi V., Kjeldsen S. E., Cushman W., Papademetriou V., Weber M., Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Pressure 2007 16 2 80 86 2-s2.0-34447315518 10.1080/ 08037050701395571 (Pubitemid 47050368)
77. Black H. R., Elliott W. J., Grandits G., Grambsch P., Lucente T., White W. B., Neaton J. D., Grimm R. H., Hansson L., Lacourcière Y., Muller J., Sleight P., Weber M. A., Williams G., Wittes J., Zanchetti A., Anders R. J., Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. Journal of the American Medical Association 2003 289 16 2073 2082 2-s2.0-0037851836 10.1001/jama.289.16.2073 (Pubitemid 37430209)
78. Ernst M. E., Carter B. L., Goerdt C. J., Steffensmeier J. J. G., Phillips B. B., Zimmerman M. B., Bergus G. R., Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006 47 3 352 358 2-s2.0-33644981542 10.1161/01.HYP.0000203309. 07140.d3 (Pubitemid 43740274)
79. Khosla N., Chua D. Y., Elliott W. J., Bakris G. L., Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? Journal of Clinical Hypertension 2005 7 6 354 356 2-s2.0-27744579877
80. Sarafidis P. A., Bakris G. L., State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. Journal of Clinical Hypertension 2008 10 2 130 139 2-s2.0-42049112222 10.1111/j.1751-7176.2008.07309.x
81. Vlase H. L., Panagopoulos G., Michelis M. F., Effectiveness of furosemide in uncontrolled hypertension in the elderly: role of renin profiling. American Journal of Hypertension 2003 16 3 187 193 2-s2.0-0037336260 10.1016/S0895- 7061(02)03260-0 (Pubitemid 36293062)
82. Sarafidis P. A., Proteinuria: natural course, prognostic implications and therapeutic considerations. Minerva Medica 2007 98 6 693 711 2-s2.0-38849150966 (Pubitemid 351196060)
83. Nishizaka M. K., Zaman M. A., Calhoun D. A., Efficacy of low-dose spironolactone in subjects with resistant hypertension. American Journal of Hypertension 2003 16 11 I 925 930 2-s2.0-0142231538 10.1016/S0895-7061(03)01032- X (Pubitemid 37315491)
84. Alper A. B. Jr., Calhoun D. A., Contemporary management of refractory hypertension. Current hypertension reports 1999 1 5 402 407 2-s2.0-0033205277
85. Nishizaka M. K., Calhoun D. A., The role of aldosterone antagonists in the management of resistant hypertension. Current Hypertension Reports 2005 7 5 343 347 2-s2.0-27544438071 (Pubitemid 41535772)
86. Pimenta E., Gaddam K. K., Oparil S., Mechanisms and treatment of resistant hypertension. Journal of Clinical Hypertension 2008 10 3 239 244 2-s2.0-43549105386 10.1111/j.1751-7176.2008.08143.x
87. Lane D. A., Beevers D. G., Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. Journal of Hypertension 2007 25 12 2515 2516 2-s2.0-35848965472 10.1097/HJH.0b013e3282f254d9 (Pubitemid 350060395)
88. Dora J. M., jmdora@gmail.com Kramer C. K., Canani L. H., Standards of medical care in diabetes2008: response to Hirsch, Inzucchi, and Kirkman. Diabetes Care 2008 31 5, article e45 10.2337/dc08-0109
89. Yusuf S., Teo K. K., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P., Anderson C., Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine 2008 358 15 1547 1559 2-s2.0-42049107348 10.1056/NEJMoa0801317 (Pubitemid 351522739)
90. Pfeffer M. A., McMurray J. J. V., Velazquez E. J., Rouleau J. L., Kober L., Maggioni A. P., Solomon S. D., Swedberg K., Van de Werf F., White H., Leimberger J. D., Henis M., Edwards S., Zelenkofske S., Sellers M. A., Califf R. M., Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine 2003 349 20 1893 1906 2-s2.0-0242490542 10.1056/NEJMoa032292 (Pubitemid 37409706)
91. Solomon S. D., Appelbaum E., Manning W. J., Verma A., Berglund T., Lukashevich V., Papst C. C., Smith B. A., Dahlöf B., Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009 119 4 530 537 2-s2.0-61349170589 10.1161/CIRCULATIONAHA.108.826214
92. Parving H. H., Persson F., Lewis J. B., Lewis E. J., Hollenberg N. K., Aliskiren combined with losartan in type 2 diabetes and nephropathy. New England Journal of Medicine 2008 358 23 2433 2446 2-s2.0-44849114597 10.1056/NEJMoa0708379 (Pubitemid 351793017)
93. Jamerson K., Weber M. A., Bakris G. L., Dahlöf B., Pitt B., Shi V., Hester A., Gupte J., Gatlin M., Velazquez E. J., Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New England Journal of Medicine 2008 359 23 2417 2428 2-s2.0-57349138291 10.1056/NEJMoa0806182
94. Saseen J. J., Carter B. L., Brown T. E. R., Elliott W. J., Black H. R., Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension 1996 28 1 109 114 2-s2.0-0029979802 (Pubitemid 26231098)
95. Gashti C. N., Bakris G. L., The role of calcium antagonists in chronic kidney disease. Current Opinion in Nephrology and Hypertension 2004 13 2 155 161 2-s2.0-1642290929 10.1097/00041552-200403000-00003 (Pubitemid 38373137)
96. Mann S. J., Combined alpha/beta-blockade: an underused approach to the treatment of resistant hypertension. Journal of Clinical Hypertension 2007 9 9 663 666 2-s2.0-38449097482 10.1111/j.1524-6175.2007.07225.x
97. Sica D. A., Minoxidil: an underused vasodilator for resistant or severe hypertension. Journal of Clinical Hypertension 2004 6 5 283 287 2-s2.0-3042821984
98. Black H. R., Bakris G. L., Weber M. A., Weiss R., Shahawy M. E., Marple R., Tannoury G., Linas S., Wiens B. L., Linseman J. V., Roden R., Gerber M. J., Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. Journal of Clinical Hypertension 2007 9 10 760 769 2-s2.0-43049099531 10.1111/j.1524-6175.2007.07244.x
99. Nakov R., Pfarr E., Eberle S., Darusentan: an effective endothelin receptor antagonist for treatment of hypertension. American Journal of Hypertension 2002 15 7, part 1 583 589 2-s2.0-0036634351 10.1016/S0895-7061(02) 02933-3 (Pubitemid 34734804)
100. Schlaich M. P., Krum H., Esler M. D., New therapeutic approaches to resistant hypertension. Current Hypertension Reports 2010 12 4 296 302 2-s2.0-77952633443 10.1007/s11906-010-0119-1
101. Raichlin E., Prasad A., Mathew V., Kent B., Holmes D. R., Pumper G. M., Nelson R. E., Lerman L. O., Lerman A., Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 2008 52 3 522 528 2-s2.0-52049097771 10.1161/HYPERTENSIONAHA.108.113068
102. Kostis J. B., Packer M., Black H. R., Schmieder R., Henry D., Levy E., Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. American Journal of Hypertension 2004 17 2 103 111 2-s2.0-1642452758 10.1016/j.amjhyper.2003.09.014 (Pubitemid 38125125)
103. Brown M. J., Coltart J., Gunewardena K., Ritter J. M., Auton T. R., Glover J. F., Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clinical Science 2004 107 2 167 173 2-s2.0-4043116249 10.1042/CS20030381 (Pubitemid 39070933)
104. Ambühl P. M., Tissot A. C., Fulurija A., Maurer P., Nussberger J., Sabat R., Nief V., Schellekens C., Sladko K., Roubicek K., Pfister T., Rettenbacher M., Volk H. D., Wagner F., Müller P., Jennings G. T., Bachmann M. F., A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. Journal of Hypertension 2007 25 1 63 72 2-s2.0-33845362874 10.1097/HJH.0b013e32800ff5d6 (Pubitemid 44885665)
105. Sanchez L. A., Illig K., Levy M., Jaff M., Trachiotis G., Shanley C., Irwin E., Jim J., Rossing M., Kieval R., Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology. Annals of Vascular Surgery 2010 24 2 178 184 2-s2.0-75149134770 10.1016/j.avsg.2009.10.003
106. Campese V. M., Kogosov E., Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995 25 4, part 2 878 882 2-s2.0-0028953330
107. Campese V. M., Kogosov E., Koss M., Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. American Journal of Kidney Diseases 1995 26 5 861 865 2-s2.0-0028858468
108. Krum H., Schlaich M., Whitbourn R., Sobotka P. A., Sadowski J., Bartus K., Kapelak B., Walton A., Sievert H., Thambar S., Abraham W. T., Esler M., Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. The Lancet 2009 373 9671 1275 1281 2-s2.0-64049084640 10.1016/S0140-6736(09)60566-3
109. Schlaich M. P., Sobotka P. A., Krum H., Lambert E., Esler M. D., Renal sympathetic-nerve ablation for uncontrolled hypertension. New England Journal of Medicine 2009 361 9 932 934 2-s2.0-69349085170 10.1056/NEJMc0904179